These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23588081)

  • 1. Protein modelling of a novel KIT mutation (N567Y) in the gastrointestinal stromal tumour.
    Alyuruk H; Calibasi G; Cavas L; Baskin Y; Oztop I; Ellidokuz H; Yilmaz U
    Eur J Cancer; 2013 Jul; 49(10):2449-52. PubMed ID: 23588081
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
    Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.
    Loughrey MB; Waring PM; Dobrovic A; Demetri G; Kovalenko S; McArthur G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6205-6; author reply 6206-7. PubMed ID: 17062700
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
    Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
    Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and leiomyosarcoma.
    Trent JC; Lazar AJ; Zhang W
    Future Oncol; 2007 Dec; 3(6):629-37. PubMed ID: 18041915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
    Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
    [No Abstract]   [Full Text] [Related]  

  • 7. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
    Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal stromal tumors (GISTs): a pathology view point.
    Sornmayura P
    J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
    De Giorgi U
    J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
    [No Abstract]   [Full Text] [Related]  

  • 10. Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach.
    Rajasekaran R; Sethumadhavan R
    Amino Acids; 2010 Aug; 39(3):651-60. PubMed ID: 20140688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
    Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of GIST.
    Blanke C
    Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286
    [No Abstract]   [Full Text] [Related]  

  • 13. Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.
    Grabellus F; Ebeling P; Worm K; Sheu SY; Antoch G; Frilling A; Schmid KW
    Gut; 2007 Jul; 56(7):1025-6. PubMed ID: 17566038
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
    Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for neoadjuvant treatment with Gleevec for large rectal gastrointestinal stromal tumors?
    Wasserberg N; Nunoo-Mensah JW; Beart RW; Ker TS
    Int J Colorectal Dis; 2007 Aug; 22(8):981-2. PubMed ID: 16583196
    [No Abstract]   [Full Text] [Related]  

  • 16. [A new genetic diagnosis of familiar gastrointestinal stromal tumour].
    Wadt K; Andersen MK; Hansen TV; Gerdes AM
    Ugeskr Laeger; 2012 May; 174(21):1462-4. PubMed ID: 22640790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive gastrointestinal stromal tumour of the oesophagus with homozygous KIT exon 11 deletion mutation.
    Cho J; Kang GH; Kim KM; Park J; Shim YM
    Pathology; 2012 Apr; 44(3):260-1. PubMed ID: 22437744
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
    Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY
    Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
    Heinrich MC; Corless CL
    J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.